With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...

AstraZeneca's (AZN) Enhertu reduces the risk of disease progression by 72% in HER2-positive metastatic breast cancer. Imfinzi plus chemotherapy triples patient survival at three years in ES-SCLC.

(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) Enhertu has been approved in the European Union as monotherapy for the treatment of adult patients with advanced non-small ...

Enhertu — A Key Oncology Drug for AZN Enhertu, a specifically engineered HER2-directed antibody-drug conjugate (ADC), is jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.

AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialise Enhertu in March 2019 and Datroway (datopotamab deruxtecan) in July 2020, except in Japan where ...

Britain’s cash-strapped Labour government cannot fold to every corporate lobbying campaign. But it ought to heed Soriot and ...

AstraZeneca said on Monday a mid-stage trial of its cancer drug Enhertu, co-developed with Daiichi Sankyo, showed positive results across multiple HER2-expressing advanced solid tumours in heavily ...

(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo Company, Limited (DSKYF.PK) said that enhertu significantly improved progression-free survival in destiny-breast03 head-to-head phase 3 ...

AstraZeneca and Daiichi Sankyo have officially escalated the competition in HER2-positive breast cancer treatment. Thursday, AZ and Daiichi said the FDA has approved their rising star Enhertu for ...

(Reuters) -AstraZeneca said a late-stage trial had confirmed the benefit of breast cancer drug Enhertu in patients with an advanced form of the disease who had been previously treated with another ...

ENHERTU ® (fam-trastuzumab deruxtecan-nxki) is the lead product in the ADC Franchise of the Daiichi Sankyo Cancer Enterprise and the most advanced program in AstraZeneca’s ADC scientific platform.